维生素C通过向GAPDH选择性地杀死KRAS和BRAF突变结直肠癌细胞
Jihye Yun1, Edouard Mullarky2, Changyuan Lu3
1Meyer Cancer Center, Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA.
概括
高剂量的维生素C通过诱导氧化应激和能量危机选择性地杀死具有KRAS或BRAF突变的结直肠癌细胞. 这一发现为这些难以治疗的癌症提供了潜在的新疗法.
科学领域:
- 癌症学
- 生物化学
- 分子生物学
背景情况:
- 结肠直肠癌 (CRC) 经常携带KRAS或BRAF突变,导致对向疗法的耐药性.
- 对KRAS/ BRAF突变CRC的有效治疗策略仍然有限.
研究的目的:
- 研究高剂量维生素C对KRAS或BRAF突变结直肠癌细胞的选择性抗癌作用.
- 阐明这些特定癌症类型中维生素C诱导的细胞死亡的潜在分子机制.
主要方法:
- 使用了具有KRAS或BRAF突变的培养人体CRC细胞和野生类型的对应物.
- 通过GLUT1评估高剂量维生素C (以脱酸盐,DHA的形式) 摄入的影响.
- 测量了氧化应激,谷氨水平和甘甲基3-酸脱酶 (GAPDH) 的活性.
- 在Apc/Kras (G12D) 突变小鼠模型中评估瘤生长.
主要成果:
- 在培养的KRAS或BRAF突变CRC细胞中,高维生素C水平可选择性诱导细胞死亡.
- 通过GLUT1增加DHA吸收,导致氧化应激和谷氨耗尽.
- 累积的活性氧物种使GAPDH失活,导致突变细胞的能量危机.
- 在相关的小鼠模型中,高剂量维生素C显示抑制瘤生长.
结论:
- 高剂量的维生素C对KRAS/ BRAF突变结直肠癌具有选择性细胞毒性.
- 这种机制涉及DHA诱导的氧化应激,GAPDH抑制和随后的代谢崩.
- 维生素C代表了对KRAS和BRAF突变CRC的有希望的治疗途径.
更多相关视频
10:13A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
Published on: July 3, 2013
11.8K
07:49Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
6.6K
相关概念视频
The Ras Gene
7.5K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
7.5K
Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies
1.8K
1.8K
Inhibition of Cdk Activity
6.2K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Small GTPases - Ras and Rho
5.7K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
5.7K
Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
